医療薬学
Online ISSN : 1882-1499
Print ISSN : 1346-342X
ISSN-L : 1346-342X
41 巻 , 9 号
選択された号の論文の9件中1~9を表示しています
一般論文
  • 原 茉梨絵, 中島 寿久, 原島 寿江, 龍島 靖明, 清水 千佳子, 公平 誠, 温泉川 真由, 山本 春風, 橋本 淳, 田辺 裕子, ...
    2015 年 41 巻 9 号 p. 603-611
    発行日: 2015/09/10
    公開日: 2016/09/10
    ジャーナル フリー

    Here we report the efficacy of the prophylactic antiemetic therapy that is recommended as high emetic risk by the American Society of Clinical Oncology (ASCO) guideline (2011) for anthracyclines and cyclophosphamide combination therapy (AC, CEF therapy) as neoadjuvant or adjuvant chemotherapy in breast cancer. In the National Cancer Center Hospital, aprepitant (APR) has been used in AC, CEF therapy since 2010, and additional day 2-4 dosages of dexamethasone (DEX) since 2012, following the ASCO guidelines (2006 / 2011). However, neither the efficacy nor the details of DEX dosage given concomitantly with APR in AC, CEF therapy have been fully established. We retrospectively investigated the incidence of nausea and vomiting before and after the introduction of APR therapy with or without additional use of DEX in breast cancer patients treated with preoperative or postoperative AC, CEF therapy in the hospital to confirm the efficacy and safety of the prophylactic antiemetic therapy. In 338 patients who received the treatment between January 2009 and December 2010, the incidence of vomiting decreased in the APR administered group (P = 0.020), while the degree of nausea increased (P = 0.003). In addition, in 369 patients who received the treatment between May 2011 and May 2013, the degree of nausea was significantly improved by APR with additional day 2-4 DEX dosages (P < 0.001). No adverse events associated with the additional dosage of DEX were observed. These results seem to positively support the efficacy of antiemetic prophylaxis recommended by the ASCO guideline (2011).

  • 齊藤 順平, 小村 誠, 寺門 浩之, 石川 洋一
    2015 年 41 巻 9 号 p. 612-623
    発行日: 2015/09/10
    公開日: 2016/09/10
    ジャーナル フリー

    Tazobactam/piperacillin (TAZ/PIPC) is a broad-spectrum antibiotic with anti-pseudomonal activity. Vancomycin (VCM) is primarily active against gram-positive bacteria, including methicillin-resistant Staphylococcus aureus. These drugs are commonly used together as broad empirical therapy for hospitalized patients with Pseudomonas aeruginosa infections, catheter-associated infection and sepsis.

    There have been several recent reports of increased nephrotoxicity associated with the concomitant use of VCM and TAZ/PIPC in adults. Our objective is to determine whether the addition of TAZ/PIPC leads to an increased incidence of nephrotoxicity in pediatric patients receiving VCM and to explore potential confounding factors of acute kidney injury (AKI).

    We conducted a retrospective study to assess the incidence of AKI in pediatric patients treated with VCM alone, TAZ/PIPC alone or concomitant use (120 cases in each group). AKI was defined as an increase in serum creatinine (SCr) > 50% in serial creatinine measurements and indicates abnormal SCr level.

    Fifteen (VCM), 6 (TAZ/PIPC) and 30 (concomitant use) patients met the criteria for AKI and the SCr increase rates were 38.2%, 34.8% and 61.7%. Long duration of therapy and high VCM trough levels were observed in patients with AKI. The incidence of VCM-related AKI was commonly associated with > 1% of fractional excretion rate of sodium, hyponatremia, hyperkalemia, metabolic acidosis and < 20 of blood urea nitrogen/SCr ratio, suggesting that AKI results from renal tubular injury.

    We observed an increased incidence of AKI in pediatric patients with concomitant use of VCM and TAZ/PIPC, and require pharmaceutical management based on laboratory data.

ノート
  • 二神 咲子, 由井薗 陽一, 槙林 智子
    2015 年 41 巻 9 号 p. 624-629
    発行日: 2015/09/10
    公開日: 2016/09/10
    ジャーナル フリー
    The self-injection of insulin or GLP-1 receptor agonists causes mental distress to patients, and pen-type injectors and their needles are being continually developed and improved to alleviate such distress. In Saiseikai Fukuoka General Hospital, Nanopass® 34G Needle II 4 mm (T34) , the thinnest needle available on the market, has been used. To examine usability for patients after changing the injector needle from BD Micro-Fine PlusTM 31G 5 mm (BD31) or Nanopass® 33G Needle 5 mm (T33) to T34, a questionnaire survey was conducted. Sensitive patients perceived differences when changing their injector needles not only from BD31 to T34, with a difference of 3G, but also from T33 to T34, with a smaller difference of 1G. In both cases, patients' perceptions improved as a result of improvements in factors markedly influencing them: frequency of subcutaneous bleeding, pain when puncturing of the needle, and liquid leakage when removing the needle. The results of this study confirmed the usefulness of thinner and shorter injector needles to alleviate patients' distress, suggesting the necessity of considering their usability of needles during guidance on selfinjection.
  • 川本 英子, 浜原 安奈, 兼光 朝子, 髙見 陽一郎, 森山 圭, 花田 貴惠, 井上 結夏, 長瀨 彩花, 山本 温子, 小川 壮寛, ...
    2015 年 41 巻 9 号 p. 630-635
    発行日: 2015/09/10
    公開日: 2016/09/10
    ジャーナル フリー
    We recently reported that various amounts of cyclophosphamide (CP) had contaminated both the inside and outside of the blister pack, and refrigerated storage of CP oral tablets can protect healthcare workers and patients from contact CP exposure. However, the contamination from a non-volatile agent, fluorouracil (FU), and its preventive procedures are not elucidated. Here we showed high levels of FU were detected from inside the blister pack. Raman imaging showed that the FU ingredient was not attached to the surface of the tablet coating layer and had not leached out of the tablet. In addition, the amount of FU detected inside the blister pack had no significant change by physical loading including shaking and heating. Thus, the FU contamination could be because of the manufacturing environment rather than the FU oral tablets themselves. We suggest that the pharmacists should instruct the patients to administer or handle tablets and capsules containing antitumor agents without direct hand contact. In addition, pharmacists should provide information about the contamination state and effective decontamination procedures for antitumor agents.
  • 下田 賢一郎, 星野 輝彦, 塩津 和則
    2015 年 41 巻 9 号 p. 636-642
    発行日: 2015/09/10
    公開日: 2016/09/10
    ジャーナル フリー
    In the present study, we conducted a retrospective assessment of the abnormal liver and renal function test results of 156 orthopedic patients receiving sulbactam/cefoperazone (SBT/CPZ). We assessed aspartate aminotransferase (AST), alanine aminotransferase (ALT), and alkaline phosphatase levels for liver function, and serum creatinine and estimated glomerular filtration rate level for renal function. Liver function parameters after the administration of SBT/CPZ showed significantly higher values than that observed before administration. The incidence of abnormal liver function in patients was 23.1% (n = 36). Almost all abnormal liver function test results were grade 1, although grade 2 abnormal AST and ALT levels occurred in 3.2% (n = 5) and 4.5% (n = 7) of patients, respectively. Abnormal liver function of 36 patients recovered after stopping SBT/CPZ administration. In factorial analyses of abnormal liver function test results after SBT/CPZ administration, the abnormal liver function group (n = 36) showed significantly higher AST and ALT values before administration than the normal liver function group (n = 120). In contrast, there were no significant changes in renal function before and after the administration of SBT/CPZ. These results suggest that SBT/CPZ frequently induce hepatic dysfunction. In particular, patients with high AST and ALT levels should be closely followed up to check for hepatic dysfunction caused by SBT/CPZ.
  • Ryohei Takahashi, Koichi Imai, Yoshiaki Yamamoto, Yukitoshi Takahashi, ...
    2015 年 41 巻 9 号 p. 643-650
    発行日: 2015/09/10
    公開日: 2016/09/10
    ジャーナル フリー

    We herein developed a method that required a smaller sample volume to rapidly determine plasma stiripentol (STP) concentrations in patients with Dravet syndrome by means of reverse-phase high-performance liquid chromatography (HPLC) using a fluorescence detector (Ex/Em: 210/400 nm). A pretreatment involved simple deproteinization with acetonitrile. A Discovery® HS C18 column, 3 μm, 4.6 mm × 150 mm was used for isolation by HPLC. The mobile phase, consisting of 25 mM phosphate buffer (pH 2.6) and acetonitrile (43:57, v/v), had a flow rate of 1.5 mL/min. The retention time was 4.6 minutes, and the lower limit of quantification was 0.05 μg/mL. Specificity testing revealed no influence on the peak. A plasma sample of 10 μL was sufficient to measure plasma STP concentrations in patients with Dravet syndrome; thus, the burden on these patients was markedly reduced. These results suggest that the determination of plasma STP concentrations was useful.

  • 松永 宣史, 須田 慎吾, 畑中 絵里子, 池田 寿昭, 上野 琢也, 奥山 清
    2015 年 41 巻 9 号 p. 651-655
    発行日: 2015/09/10
    公開日: 2016/09/10
    ジャーナル フリー

    In the treatment of patients with severe drug eruption such as Stevens-Johnson syndrome and toxic epidermal necrosis (TEN), it is important to prohibit the use of suspected drugs. However, the use of antibiotics for severe infection diseases is unavoidable, even when an antibiotic is the suspected drug. In such a case, it is necessary for rapid and discreet determination of antibiotic selection.

    A 61-year-old patient was hospitalized with TEN suspected to be caused by ceftriaxone or loxoprofen. He had been treated with levofloxacin for primate pneumonia and daptomycin for epidermal necrosis and peeling spanning the whole body in the intensive care unit (ICU). However, his lung oxygenation capacity rapidly deteriorated while respiratory therapy was performed using a respirator. We diagnosed him with ventilator-associated pneumonia (VAP) by considering his clinical situation, including X-ray results and bronchoscopy findings. Then we changed the antibiotics to aztreonam for Pseudomonas aeruginosa and vancomycin for methicillin-resistant Staphylococcus aureus (MRSA) based on the results of the Gram stain of his sputum. In the next day, his lung oxygenation capacity was improved. After five days, MRSA and Corynebacterium were detected from the sputum and the Pseudomonas aeruginosa culture test was negative. Thus we decided to discontinue aztreonam. Consequently both TEN and VAP improved.

    Through this case we were able to confirm that you must firstly consider the clinical conditions of the patient and his medical history, and then the results of microbe culture tests and drug sensitivity tests accordingly in the case of such a severe drug eruption.

  • 向井 潤一, 石黒 友紀, 須田 哲史, 尾鳥 勝也, 厚田 幸一郎
    2015 年 41 巻 9 号 p. 656-666
    発行日: 2015/09/10
    公開日: 2016/09/10
    ジャーナル フリー

    To compare the efficacy and safety of hydro- and lipophilic strong statins in patients with type II diabetes mellitus and hyperlipidemia, we conducted a meta-analysis. We investigated the literature published before April 2013 using MEDLINE, CENTRAL, and Ichushi-Web. We adopted a randomized controlled trial design involving the administration of hydro- and lipophilic strong statins to patients with type II diabetes mellitus and hyperlipidemia. As parameters of the efficacy, serum lipid levels were used. Concerning the safety, several parameters, including the hemoglobin A1c value, were used. Of 299 reports, 9 were adopted. In the hydrophilic strong statin group, there was a significant decrease in the low-density lipoprotein cholesterol level. In addition, there was a significant increase in the high-density lipoprotein cholesterol level. Concerning the safety, there was a significant increase in the aspartate aminotransferase level in the hydrophilic strong statin group. There were no significant differences in any other safety parameter between the hydrophilic and lipophilic strong statin groups. The results of this study may contribute to clinical evaluation for the comprehensive treatment of patients with type II diabetes mellitus and hyperlipidemia.

  • 野口 義紘, 江﨑 宏樹, 浅野 祥子, 横井 貴文, 臼井 一将, 加藤 未紗, 齊藤 康介, 舘 知也, 寺町 ひとみ
    2015 年 41 巻 9 号 p. 667-675
    発行日: 2015/09/10
    公開日: 2016/09/10
    ジャーナル フリー

    With the escalation of pollinosis prevalence and promotion of self-medication, the importance of the anti-allergic Rxto-OTC-switched agents has been increasing. Moreover, the law amendment on related proprietary drugs lifted the ban on selling these drugs over the Internet, making them more easily accessible by ordinary citizens. Because of this, safety assurance about drug information supplementary materials from pharmacists is desired. Therefore, we assessed safety signals by detecting adverse events caused by anti-allergic Rx-to-OTC-switched agents.

    We analyzed data from the Japanese Adverse Drug Event Report for April 2004 to September 2013. We surveyed 10 types of adverse events, including hepatic disorders, severe cutaneous adverse reactions, and anaphylactic reactions. We used the reported odds ratio as the safety index.

    Signals were detected in hepatic disorders with all medicines, except for emedastine and diphenhydramine. In addition, signals were detected in hepatic disorders with all of the anti-allergic Rx-to-OTC-switched agents, independent of sex and age range. The results of this study suggest that people who purchase anti-allergic Rx-to-OTC-switched agents should be alerted to the associated adverse events. Moreover, the results showed that using anti-allergic Rx-toOTC-switched agents potentially leads to severe adverse events, indicating that it is essential to provide drug information regardless of risk classification for the proper use of the drugs.

feedback
Top